Affiliation:
1. Department of Internal Oncology, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, People's Republic of China
2. Radiation Oncology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA
Abstract
Abstract
Background.
Complications from skeletal-related events (SREs) constitute a challenge in the care of cancer patients with bone metastasis (BM).
Objectives.
This study evaluated the comparative effectiveness of pamidronate, ibandronate, zoledronate, and denosumab in reducing the morbidity of SREs in cancer patients with BM.
Methods.
Medline (1948 to January 2014), Embase (1980 to January 2014), the Cochrane Library (2014 issue 1), and Web of Science with Conference Proceedings (1970 to January 2014) were searched. Only randomized controlled trials assessing denosumab, bisphosphonates, or placebo in cancer patients with BM were included. The primary outcomes were SREs and SREs by type. The network meta-analysis (NMA) was performed with a random-effects Bayesian model.
Results.
The NMA included 14 trials with 10,192 patients. Denosumab was superior to placebo in reducing the risk of SREs (odds ratio [OR]: 0.49; 95% confidence interval [CI]: 0.31–0.75), followed by zoledronate (OR: 0.57; 95% CI: 0.41–0.77) and pamidronate (OR: 0.55; 95% CI: 0.41–0.72). Ibandronate compared with placebo could not reduce the risk of SREs. Denosumab was superior to placebo in reducing the risk of pathologic fractures (OR: 0.50; 95% CI: 0.32–0.79), followed by zoledronate (OR: 0.61; 95% CI: 0.43–0.86). Denosumab was superior to placebo in reducing the risk of radiation (OR: 0.51; 95% CI: 0.35–0.75), followed by pamidronate (OR: 0.67; 95% CI: 0.52–0.86) and zoledronate (OR: 0.70; 95% CI: 0.52–0.96).
Conclusion.
This NMA showed that denosumab, zoledronate, and pamidronate were generally effective in preventing SREs in cancer patients with BM. Denosumab and zoledronate were also associated with reductions in the risk of pathologic fractures and radiation compared with placebo. Denosumab was shown to be the most effective of the bone-targeted agents.
Funder
Natural Science Foundation of China
Publisher
Oxford University Press (OUP)
Cited by
44 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献